Cargando…

Baseline monocyte and its classical subtype may predict efficacy of PD-1/PD-L1 inhibitor in cancers

Background: Programmed death 1 (PD-1)/ programmed death-ligand 1 (PD-L1) inhibitor is one of the most popular immune therapies. Biomarkers for predicting response are highly needed, but no biomarkers are widely used till now. Patients and methods: From February 2018 to April 2019, pan-cancer patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Yilin, Lin, Shuchen, Zhang, Ping, Zhang, Jian, Ji, Dongmei, Tao, Zhonghua, Hu, Xichun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2021
Materias:	Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846968/ https://www.ncbi.nlm.nih.gov/pubmed/33440424 http://dx.doi.org/10.1042/BSR20202613

Ejemplares similares

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
por: Zhang, Wei, et al.
Publicado: (2019)

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
por: Huang, Yafang, et al.
Publicado: (2019)

Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes
por: Ni, Yunbi, et al.
Publicado: (2022)

PD‐1/PD‐L1 inhibitors‐based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies
por: Ding, Lei, et al.
Publicado: (2021)

Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China
por: Teng, Meng‐Meng, et al.
Publicado: (2021)

The effects and safety of PD‐1/PD‐L1 inhibitors on head and neck cancer: A systematic review and meta‐analysis
por: Wang, Bi‐Cheng, et al.
Publicado: (2019)

Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
por: Wang, Zhengyi, et al.
Publicado: (2020)

Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer
por: Qiu, Xin, et al.
Publicado: (2023)

PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling
por: Gao, Hongmin, et al.
Publicado: (2019)

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2020)

Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis
por: Geng, Yichao, et al.
Publicado: (2021)

Prostasin regulates PD-L1 expression in human lung cancer cells
por: Chen, Li-Mei, et al.
Publicado: (2021)

Concordance of PD‐1 and PD‐L1 (B7‐H1) in paired primary and metastatic clear cell renal cell carcinoma
por: Eckel‐Passow, Jeanette E., et al.
Publicado: (2019)

High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma
por: Chen, Xi, et al.
Publicado: (2022)

PD‐1/PD‐L1 Blockade Therapy in Advanced Non‐Small‐Cell Lung Cancer: Current Status and Future Directions
por: Xia, Liliang, et al.
Publicado: (2019)

Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines
por: Bräutigam, Karen, et al.
Publicado: (2021)

Combination of PD‐1/PD‐L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma
por: van Gulijk, Mandy, et al.
Publicado: (2022)

Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis
por: Li, Xiao-Song, et al.
Publicado: (2020)

Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab
por: Lambert, Stacie L., et al.
Publicado: (2022)

Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood
por: Rad Pour, Soudabeh, et al.
Publicado: (2021)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer
por: Zhu, Xinxin, et al.
Publicado: (2018)

Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib
por: Wang, Jinfeng, et al.
Publicado: (2023)

Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma
por: Koh, Young Wha, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

Prognostic significance of PD‐L2 expression in patients with oral squamous cell carcinoma—A comparison to the PD‐L1 expression profile
por: Weber, Manuel, et al.
Publicado: (2019)

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
por: Kurino, Taiki, et al.
Publicado: (2020)

Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer
por: Chen, Yu, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study
por: Chen, Mifen, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy
por: Schetters, Sjoerd T T, et al.
Publicado: (2020)

Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes
por: Lou, Jiaying, et al.
Publicado: (2021)

Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma
por: Hollander, Peter, et al.
Publicado: (2018)

Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients
por: Gérard, Alexandre, et al.
Publicado: (2021)

The lymphocyte-to-monocyte ratio could predict the efficacy of PD-1 inhibitors in patients with advanced cancer
por: Xiao, Li, et al.
Publicado: (2020)

PD-1 as a potential target in cancer therapy
por: McDermott, David F, et al.
Publicado: (2013)

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
por: Orme, Jacob J, et al.
Publicado: (2020)

PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2021)

Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
por: Chen, Shiyun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2lq77h82ope1d6ic0m2mtocdlq